Literature DB >> 26817289

Pregabalin Abuse amongst Opioid Substitution Treatment Patients.

S McNamara, S Stokes, R Kilduff, A Shine.   

Abstract

Pregabalin (Lyrica®) is used in treating epilepsy, nerve pain and anxiety. Pregabalin was initially thought to have a low misuse potential however there are emerging reports of Pregabalin being abused. A study was commenced at the National Drug Treatment Centre's (NDTC) Drug Analysis Laboratory to determine the level of usage of Pregabalin within the addiction services population in Ireland. A total of 498 urine samples representing samples from 440 individual opioid substitution patients, initially screened by immunoassay for drugs of abuse, were subjected to further analysis for Pregabalin by Liquid Chromatography/Mass Spectrometry (LC/MS). Of 440 patients tested, 39 tested positive for Pregabalin (9.2%). Only 10 patients from this group were prescribed this drug to our knowledge thus giving an estimated rate of misuse of 7.0%. Other drugs detected in the Pregabalin positive patients were Opiates (31.8%), Cocaine (11.4%), Benzodiazepines (79.5%) and Cannabis (77.8%). Our study confirms that Pregabalin abuse is taking place amongst the addiction services population. We believe that misuse of this prescription drug is a serious emerging issue which should be monitored carefully.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26817289

Source DB:  PubMed          Journal:  Ir Med J        ISSN: 0332-3102


  13 in total

Review 1.  Abuse and Misuse of Pregabalin and Gabapentin.

Authors:  Kirk E Evoy; Megan D Morrison; Stephen R Saklad
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

2.  Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France.

Authors:  Damien Driot; Emilie Jouanjus; Stéphane Oustric; Julie Dupouy; Maryse Lapeyre-Mestre
Journal:  Br J Clin Pharmacol       Date:  2019-03-28       Impact factor: 4.335

3.  Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition.

Authors:  Rob Hill; William L Dewey; Eamonn Kelly; Graeme Henderson
Journal:  Br J Pharmacol       Date:  2018-05-07       Impact factor: 8.739

4.  Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample.

Authors:  Kirk E Evoy; Jordan R Covvey; Alyssa M Peckham; Kelly R Reveles
Journal:  Int J Clin Pharm       Date:  2021-01-02

5.  Risk to heroin users of polydrug use of pregabalin or gabapentin.

Authors:  Abigail Lyndon; Suzanne Audrey; Claudia Wells; Erica S Burnell; Suzanne Ingle; Rob Hill; Matthew Hickman; Graeme Henderson
Journal:  Addiction       Date:  2017-05-15       Impact factor: 6.526

6.  Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database.

Authors:  Jean-Baptiste Bossard; Camille Ponté; Julie Dupouy; Maryse Lapeyre-Mestre; Emilie Jouanjus
Journal:  Clin Drug Investig       Date:  2016-09       Impact factor: 2.859

7.  Global patterns of opioid use and dependence: harms to populations, interventions, and future action.

Authors:  Louisa Degenhardt; Jason Grebely; Jack Stone; Matthew Hickman; Peter Vickerman; Brandon D L Marshall; Julie Bruneau; Frederick L Altice; Graeme Henderson; Afarin Rahimi-Movaghar; Sarah Larney
Journal:  Lancet       Date:  2019-10-23       Impact factor: 79.321

8.  Intentional Drug Overdose Involving Pregabalin and Gabapentin: Findings from the National Self-Harm Registry Ireland, 2007-2015.

Authors:  Caroline Daly; Eve Griffin; Darren M Ashcroft; Roger T Webb; Ivan J Perry; Ella Arensman
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

9.  Nonmedical Use of Antihistaminergic Anxiolytics and Other Prescription Drugs among Persons with Opioid Dependence.

Authors:  Disa Dahlman; Tove Abrahamsson; Alex H Kral; Anders Hakansson
Journal:  J Addict       Date:  2016-12-20

10.  Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment.

Authors:  Michael Specka; Thomas Kuhlmann; Jürgen Sawazki; Udo Bonnet; Renate Steinert; Monika Cybulska-Rycicki; Helmut Eich; Benita Zeiske; Antje Niedersteberg; Luzia Schaaf; Norbert Scherbaum
Journal:  Front Psychiatry       Date:  2020-07-07       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.